Physician profile
Saad Karim
NPI 1730600321
$3,067.98
in general payments reported to CMS, 2019-2025
21 companies · $821 in 2025
The $821 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.13 · 2020: $144 · 2022: $294 · 2023: $1,126 · 2024: $596 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,543.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $930.05 | 2022-2025 | |
| Tris Pharma INC | $470.78 | 2023-2024 | Dyanavel Xr |
| Medtronic, INC. | $240.85 | 2023 | Linq II |
| Teva Pharmaceuticals USA, INC. | $218.67 | 2022-2025 | Austedo, Ajovy, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $164.02 | 2020-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $138.09 | 2022-2023 | Ingrezza, Ongentys |
| Eisai INC. | $117.81 | 2020-2025 | |
| Biogen, INC. | $117.20 | 2024-2025 | Vumerity, Tysabri, Skyclarys |
| Ucb, INC. | $96.13 | 2024-2025 | Briviact, Fintepla |
| Akcea Therapeutics, INC. | $87.13 | 2019 | |
| Lilly USA, LLC | $76.72 | 2022-2025 | Emgality, Kisunla |
| Lundbeck LLC | $73.11 | 2025 | Vyepti |
| Tg Therapeutics, INC. | $57.30 | 2025 | |
| Amneal Pharmaceuticals LLC | $50.32 | 2022-2024 | Rytary |
| Argenx US, INC. | $50.07 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $35.97 | 2022-2025 | |
| Amgen INC. | $32.76 | 2024 | Uplizna |
| Horizon Therapeutics Plc | $29.92 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $29.62 | 2025 | Rexulti |
| Aucta Pharmaceuticals, INC. | $26.69 | 2025 | Motpoly Xr |
| Genentech USA, INC. | $24.77 | 2025 | Tnkase |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saad Karim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.